Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Landiolol hydrochloride - Ono Pharmaceutical

Drug Profile

Landiolol hydrochloride - Ono Pharmaceutical

Alternative Names: Corebeta; Landiolol hydrochloride; ONO-1101; Onoact

Latest Information Update: 29 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ono Pharmaceutical
  • Class Antiarrhythmics; Morpholines; Small molecules; Urea compounds
  • Mechanism of Action Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ventricular fibrillation; Arrhythmias; Ventricular tachycardia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Arrhythmias; Supraventricular tachycardia
  • Registered Ventricular arrhythmias
  • Phase II/III Atrial fibrillation; Atrial flutter

Most Recent Events

  • 26 Mar 2019 Registered for Ventricular arrhythmias (Recurrent) in Japan (IV)
  • 29 Oct 2018 Ono Pharmaceutical completes a phase I trial in Japan (IV) (UMIN000029348)
  • 30 Jul 2018 Preregistration for Ventricular arrhythmias (Recurrent) in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top